Table 2—

Adverse events occurring in ≥5% of patients in any treatment group

Safety population
12-week study
Extension
LAF/METPBO/METLAF/METPBO/MET
n56514229
Cough3 (5.4)01 (2.4)0
Nasopharyngitis2 (3.6)6 (11.8)6 (14.3)4 (13.8)
Worsening hypertension003 (7.1)0
Urinary tract infection1 (1.8)3 (5.9)1 (2.4)2 (6.9)
Gastroenteritis0002 (6.9)
Bursitis001 (2.4)2 (6.9)
  • Data are n (%). LAF/MET, LAF237 plus metformin group; PBO/MET, placebo plus metformin group.